Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE – Get Rating)’s share price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.93 and traded as low as $1.31. Zynerba Pharmaceuticals shares last traded at $1.40, with a volume of 148,555 shares traded.
ZYNE has been the topic of several research analyst reports. StockNews.com initiated coverage on shares of Zynerba Pharmaceuticals in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, March 9th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Zynerba Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $6.42.
The stock has a 50 day moving average of $1.91 and a 200 day moving average of $2.78.
Several institutional investors have recently bought and sold shares of the company. Davy Global Fund Management Ltd boosted its holdings in shares of Zynerba Pharmaceuticals by 4.9% during the first quarter. Davy Global Fund Management Ltd now owns 213,469 shares of the company’s stock worth $438,000 after purchasing an additional 9,960 shares during the period. Penserra Capital Management LLC boosted its holdings in shares of Zynerba Pharmaceuticals by 7.7% during the fourth quarter. Penserra Capital Management LLC now owns 410,062 shares of the company’s stock worth $1,180,000 after purchasing an additional 29,364 shares during the period. ETF Managers Group LLC boosted its holdings in shares of Zynerba Pharmaceuticals by 2.7% during the fourth quarter. ETF Managers Group LLC now owns 4,585,741 shares of the company’s stock worth $13,345,000 after purchasing an additional 121,967 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of Zynerba Pharmaceuticals by 701.4% during the fourth quarter. GSA Capital Partners LLP now owns 270,772 shares of the company’s stock worth $780,000 after purchasing an additional 236,984 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Zynerba Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 355,509 shares of the company’s stock worth $1,023,000 after purchasing an additional 5,737 shares during the period. Institutional investors own 32.84% of the company’s stock.
Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.
- Get a free copy of the StockNews.com research report on Zynerba Pharmaceuticals (ZYNE)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.